Imara, Inc
Imara, Inc is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Imara, Inc.
Imara, Inc is a company.
Key people at Imara, Inc.
Key people at Imara, Inc.
Imara, Inc. (IMRA) is a clinical-stage biopharmaceutical company developing novel therapeutics for rare genetic disorders of hemoglobin, primarily sickle cell disease (SCD) and other hemoglobinopathies.[1][2][3][4] Its lead product candidate, IMR-687, is a highly selective, potent small molecule inhibitor of PDE9 designed to reduce red blood cell sickling and white blood cell adherence to vessel walls, addressing unmet needs in SCD treatment.[1][2] The company serves patients with these rare diseases, operating from Boston, MA, with a focus on advancing clinical programs despite no current revenue (Q2 2023: $0 revenue, $18.2M net loss, $52M cash).[1][3]
Imara went public in March 2020 via NASDAQ IPO at $16/share, raising ~$75M, but remains pre-commercial with ~20 employees and high R&D expenses.[3] Growth momentum hinges on clinical milestones for IMR-687 and pipeline expansion into areas like cardiovascular diseases, targeting a $1.9B rare disease market by 2025.[1]
Search results present conflicting founding dates for Imara, Inc.: one source claims 1995 with early focus on rare disease therapeutics and a 2010 IND filing for IMRA-101,[1] while more consistent biopharma profiles indicate 2016 as the founding year.[3] The 2016 timeline aligns with its clinical-stage status, NASDAQ IPO in 2020 (symbol IMRA), and development of IMR-687.[2][3][4]
Little public detail exists on specific founders or their backgrounds, though the company emerged from biotech innovation targeting hemoglobin disorders.[2][4] Pivotal early traction included the 2020 IPO managed by Morgan Stanley, Citigroup, and SVB Leerink, providing capital for Phase 2 trials of IMR-687 in SCD patients.[1][3] This public debut marked a shift toward aggressive clinical advancement amid a niche but high-need rare disease space.[1]
Imara rides the rare disease biotech wave, fueled by regulatory incentives like FDA orphan drug designations, which accelerate approvals and offer market exclusivity for hemoglobinopathies affecting millions globally.[1][2] Timing aligns with surging investor interest in gene-modulating therapies for SCD—post-2020 approvals like Casgevy (CRISPR-based) validate the space, creating tailwinds for small-molecule alternatives like IMR-687 that may offer oral dosing advantages.[2]
Market forces favoring Imara include a $1.9B projected rare disease sector by 2025 and partnerships for global reach.[1] It influences the ecosystem by advancing PDE9 inhibition, potentially lowering barriers for oral SCD treatments versus infusions, while competing with big pharma entrants.[1][4]
Imara's path forward centers on IMR-687 data readouts, regulatory submissions, and pipeline diversification into cardiovascular indications, with cash supporting near-term milestones.[1] Trends like AI-driven drug discovery and SCD equity initiatives will shape progress, potentially amplifying impact if Phase 3 succeeds.[1][6] Influence may evolve via acquisitions by larger players eyeing bolt-on rare disease assets, tying back to its core mission of novel hemoglobin therapies amid a validating market.[1][3]
